- Sanofi to exercise one option to license a new ANKET®
program from Innate; After a research collaboration period, Sanofi
will be responsible for all development, manufacturing and
commercialization of the program
- Innate to receive €15m as option exercise payment
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi
(NASDAQ: SNY) announced today that Sanofi has exercised its option
to license a natural killer (NK) cell engager program in solid
tumors from Innate’s ANKET® (Antibody-based NK Cell Engager
Therapeutics) platform pursuant to the terms of the research
collaboration and license agreement signed in December 2022.
Following a research collaboration period, Sanofi will be
responsible for all development, manufacturing and
commercialization. Sanofi still retains the option to one
additional ANKET® target as per the license agreement.
Eric Vivier, Ph.D., DVM, PhD, Senior Vice President, Chief
Scientific Officer of Innate Pharma, said: “We have been
collaborating with Sanofi since 2016 and together we have made
significant progress in advancing multi-specific NK Cell Engagers
for the treatment of various cancers with two programs now in the
clinic. Building on our partnership with Sanofi, the exercise of
this option is another important milestone as we continue to grow
our ANKET® platform.”
Under the terms of the December 2022 agreement, Innate will
receive a €15m payment for the exercise of this option. Innate
Pharma is eligible for up to €1.35bn total in preclinical,
clinical, regulatory and commercial milestones plus royalties on
potential net sales.
Valeria Fantin, Ph.D., Global Head of Oncology Research at
Sanofi, states: “Sanofi is pleased with our collaboration with
Innate and continues to be excited at the potential of
investigational NK Cell Engagers. The emerging results we have seen
show promise at the possibility of offering options to patients who
have limited treatments available to them.”
About ANKET®
ANKET® (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer.
About the Innate-Sanofi research collaboration and license
agreements
The Company has a research collaboration and license agreement
with Sanofi to apply Innate’s proprietary technology to the
development of innovative multi-specific antibody formats engaging
NK cells through the activating receptors NKp46 and CD16 to kill
tumor cells.
Under the 2016 research collaboration and license agreement,
Sanofi is responsible for the development, manufacturing and
commercialization of products resulting from the research
collaboration, IPH6101/SAR’579 (Trifunctional anti-CD123 NKp46xCD16
NK cell engager) and IPH6401/SAR’514 (Trifunctional anti-BCMA
NKp46xCD16 NK cell engager). Innate Pharma is eligible to up to
€400m in development and commercial milestone payments as well as
royalties on net sales.
As part of the license agreement entered in December 2022,
Sanofi licensed IPH62 (B7-H3) and one undisclosed ANKET® programs
and has the option for one additional target. Under the terms of
the 2022 agreement, Innate Pharma is eligible to up to €1.35bn
total in preclinical, clinical, regulatory and commercial
milestones plus royalties on potential net sales.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of Natural Killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com.
Information about Innate Pharma shares:
ISIN code Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231218427387/en/
Investors
Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90
32 88 Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Grafico Azioni Innate Pharma (EU:IPH)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Innate Pharma (EU:IPH)
Storico
Da Nov 2023 a Nov 2024
